Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Benign prostatic hyperplasia. Hormonal treatment

J D McConnell¹

¹Division of Urology, University of Texas Southwestern Medical Center, Dallas, USA.

The Urologic Clinics of North America

|May 1, 1995

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prostate cancer: where are we?

Proceedings (Baylor University. Medical Center)·2006

Same author

The development of urology in the 21st century.

BJU international·2001

Same author

5 alpha-Reductase inhibitors.

Advances in protein chemistry·2001

Same author

Laparoscopic gonadectomy and excision of müllerian remnant in an adult intersex patient.

Urology·2001

Same author

Contractile protein expression in bladder smooth muscle is a marker of phenotypic modulation after outlet obstruction in the rabbit model.

The Journal of urology·2001

Same author

Alpha-blockade downregulates myosin heavy chain gene expression in human benign prostatic hyperplasia.

Urology·2001

Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026

Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026

Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026

Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026

Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026

Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026

See all related articles

Androgen withdrawal therapy, like finasteride, reduces prostate volume by 20-30% in 3-6 months for benign prostatic hyperplasia (BPH). While not as effective as surgery, it offers a good risk-benefit ratio for long-term BPH management.

Area of Science:

Urology
Pharmacology

Background:

Benign prostatic hyperplasia (BPH) is a common condition in aging men.
Androgen withdrawal therapy aims to reduce prostate size and alleviate BPH symptoms.

Purpose of the Study:

To evaluate the efficacy and limitations of androgen withdrawal therapy in managing BPH.
To assess the long-term effects and risk-benefit profile of finasteride for BPH.

Main Methods:

Review of clinical studies on androgen withdrawal therapy, including finasteride.
Analysis of prostate volume changes, symptom improvement, and uroflow data.
Consideration of biological factors limiting therapeutic efficacy.

Main Results:

Androgen withdrawal therapy causes a 20-30% prostate volume decrease in 3-6 months.

Related Experiment Videos

Finasteride shows a modest but significant long-term clinical response with preserved sexual function.

Epithelial regression is more pronounced than stromal regression.

Conclusions:

Finasteride offers an acceptable risk-benefit ratio among hormonal agents for BPH.
While less effective than surgery for immediate symptom relief, medical therapy, including finasteride, plays a growing role in BPH management.
5 alpha-reductase inhibitors may be valuable for preventing BPH progression in early stages.